HUP0100762A2 - Aromatáz-inhibítor alkalmazása férfiaknál kis androgén-ösztrogén arány és detrusor húgycső záróizom koordinációs zavar kezelésére, továbbá hím rágcsálókon végezhető, izomkoordinációs zavar vizsgálatára szolgáló eljárás - Google Patents

Aromatáz-inhibítor alkalmazása férfiaknál kis androgén-ösztrogén arány és detrusor húgycső záróizom koordinációs zavar kezelésére, továbbá hím rágcsálókon végezhető, izomkoordinációs zavar vizsgálatára szolgáló eljárás

Info

Publication number
HUP0100762A2
HUP0100762A2 HU0100762A HUP0100762A HUP0100762A2 HU P0100762 A2 HUP0100762 A2 HU P0100762A2 HU 0100762 A HU0100762 A HU 0100762A HU P0100762 A HUP0100762 A HU P0100762A HU P0100762 A2 HUP0100762 A2 HU P0100762A2
Authority
HU
Hungary
Prior art keywords
dyssynergia
men
treatment
aromatase inhibitor
bladder
Prior art date
Application number
HU0100762A
Other languages
English (en)
Inventor
Kaija Halonen
Lauri Kangas
Risto Lammintausta
Risto Santti
Tomi Streng
Antti Talo
Original Assignee
Hormos Medical Oy Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Medical Oy Ltd. filed Critical Hormos Medical Oy Ltd.
Publication of HUP0100762A2 publication Critical patent/HUP0100762A2/hu
Publication of HUP0100762A3 publication Critical patent/HUP0100762A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)

Abstract

A találmány tárgya aromatáz-inhibitor alkalmazása férfiaknál fellépői) detrusor húgycső záróizom koordinációs zavar, amely egy, a betegcsökkenő androgén-ösztrogén arányának következményeként jelentkezőhúgycső rendellenesség vagy ii) csökkenő androgén-ösztrogén aránykezelésére alkalmas gyógyszerkészítmény előállítására. A találmánykiterjed hím egyedeknél alkalmazható in vivo vizeletkiválasztásifunkció befolyásolására alkalmas vizsgálati eljárásra is, amelyneksorán a rágcsálót - az említett állapotba juttatják, - érzéstelenítik,- hólyagjába infúziós kanült vezetnek, amelyhez nyomásközvetítőt, ahúgycső távolabbi részébe vezetett és egy áramlásmérőhözcsatlakoztatott áramlási szondát csatlakoztatnak, - a hólyagba egyoldatot töltenek, amellyel vizeletürítést váltanak ki, és ahólyagnyomást és a vizeletáramlást regisztrálják az idő függvényében. Ó
HU0100762A 1997-12-12 1998-12-09 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents HUP0100762A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/989,447 US5972921A (en) 1997-12-12 1997-12-12 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
PCT/FI1998/000954 WO1999030708A2 (en) 1997-12-12 1998-12-09 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents

Publications (2)

Publication Number Publication Date
HUP0100762A2 true HUP0100762A2 (hu) 2001-08-28
HUP0100762A3 HUP0100762A3 (en) 2002-12-28

Family

ID=25535123

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100762A HUP0100762A3 (en) 1997-12-12 1998-12-09 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents

Country Status (17)

Country Link
US (2) US5972921A (hu)
EP (1) EP1043993B1 (hu)
JP (1) JP2002508322A (hu)
KR (1) KR20010032909A (hu)
CN (1) CN1281361A (hu)
AT (1) ATE235904T1 (hu)
AU (1) AU743196B2 (hu)
BR (1) BR9813534A (hu)
CA (1) CA2312347A1 (hu)
DE (1) DE69813025T2 (hu)
EE (1) EE200000346A (hu)
ES (1) ES2191358T3 (hu)
HU (1) HUP0100762A3 (hu)
NO (1) NO20002960L (hu)
NZ (1) NZ504632A (hu)
PL (1) PL341653A1 (hu)
WO (1) WO1999030708A2 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
BR0013272B1 (pt) 1999-08-13 2013-10-15 Uso de um inibidor de aromatase esteroidal
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
SK14612002A3 (sk) * 2000-04-12 2003-05-02 Novartis Ag Farmaceutická kompozícia obsahujúca inhibítor aldosterónsyntázy prípadne v kombinácii s antagonistom AT1-receptora a jej použitie
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
FI20010905A0 (fi) * 2001-05-02 2001-05-02 Vetcare Oy Uusi eläinlääke
US6607755B2 (en) 2001-06-21 2003-08-19 Michael Donald Farley Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
US6931276B2 (en) * 2002-04-29 2005-08-16 Tomi Streng Method and device for use in micturition studies
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
EP1656129A4 (en) * 2003-08-22 2009-03-11 Univ Virginia MTOR BLOCUS FOR PREVENTING HORMONE ADAPTIVE RESPONSE
CN101448490A (zh) * 2006-05-22 2009-06-03 霍尔莫斯医疗有限公司 治疗慢性非细菌性前列腺炎的选择性雌激素受体调节剂或者芳香酶抑制剂
BR112014005434B1 (pt) * 2011-09-08 2021-01-05 Novartis Ag Composições farmacêuticas compreendendo inibidor da aromatase 4,4'-[fluoro-(1h-1,2,4triazol-1-il)metilemo]bisbenzonitrila e seu método de preparação
CN102641502A (zh) * 2012-04-25 2012-08-22 中国农业大学 芳香酶抑制剂的新用途
JP6545185B2 (ja) * 2014-03-21 2019-07-17 ドン・ワ・ファーム・カンパニー・リミテッドDong Wha Pharm. Co., Ltd. インドナガコショウ抽出物を含む排尿障害の予防、治療及び改善用組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men

Also Published As

Publication number Publication date
CA2312347A1 (en) 1999-06-24
EP1043993B1 (en) 2003-04-02
JP2002508322A (ja) 2002-03-19
NO20002960D0 (no) 2000-06-09
BR9813534A (pt) 2000-11-14
HUP0100762A3 (en) 2002-12-28
US5972921A (en) 1999-10-26
DE69813025T2 (de) 2004-01-15
AU743196B2 (en) 2002-01-24
DE69813025D1 (de) 2003-05-08
ES2191358T3 (es) 2003-09-01
US6316431B1 (en) 2001-11-13
KR20010032909A (ko) 2001-04-25
EP1043993A2 (en) 2000-10-18
WO1999030708A3 (en) 1999-08-19
NO20002960L (no) 2000-08-14
ATE235904T1 (de) 2003-04-15
WO1999030708A2 (en) 1999-06-24
CN1281361A (zh) 2001-01-24
PL341653A1 (en) 2001-04-23
EE200000346A (et) 2001-10-15
AU1489799A (en) 1999-07-05
NZ504632A (en) 2001-10-26

Similar Documents

Publication Publication Date Title
HUP0100762A2 (hu) Aromatáz-inhibítor alkalmazása férfiaknál kis androgén-ösztrogén arány és detrusor húgycső záróizom koordinációs zavar kezelésére, továbbá hím rágcsálókon végezhető, izomkoordinációs zavar vizsgálatára szolgáló eljárás
US6494879B2 (en) Treating urinary retention
CA2365447C (en) Intravesicular balloon
Chang Urodynamic studies in acupuncture for women with frequency, urgency and dysuria
US20020165427A1 (en) Intravesicular device
JP2004535863A (ja) 尿道プロファイル装置ならびにそのための方法。
WO2006060248A3 (en) Pressure and temperature monitoring balloon catheter
Gregersen et al. Biomechanical wall properties and collagen content in the partially obstructed opossum esophagus
CN101991906A (zh) 一种直肠球囊扩张导管
ES2268683T3 (es) Metodo y sistema para medicion, almacenamiento, recuperacion de la informacion almacenada y analisis en linea de datos urodinamicos.
Raz et al. Carbon dioxide urethral pressure profile
Woodbury et al. Constant pressure perfusion: a method to determine obstruction in the upper urinary tract
Johnson et al. Transducer manometry and the effect of body position on anal canal pressures
JP7242688B2 (ja) 尿流動態検査装置
DE19530440C2 (de) Rektalkatheter
Harrison The urethral pressure profile
Plevnik Model of the proximal urethra: measurement of the urethral stress profile
Hasegawa et al. The effect of abdominal pressure on urinary flow rate
CN101658695B (zh) 多气囊排便引流装置
CN108903959A (zh) 一种硅胶导管用于双腔膀胱临床测压方法
Davis Urinary tract obstruction: what has been learned about it, and what is still to be learned
CN208741720U (zh) 一种带压力感受器的膀胱引流管
CN205683082U (zh) 一种前列腺及尿道测量导管
Madersbacher Combined pressure, flow, EMG and X-ray studies for the evaluation of neurogenic bladder disturbance: technique
Ronen Measurements of urethral pressure profiles in the male horse